XML 61 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Summary of the Option Unit Activity (Details)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Weighted Average Remaining Contractual Term, Grants Vested 2 years 8 months 12 days
2021 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 4,311,662
Number of units, granted | shares 71,099
Number of units, grant outstanding ending balance | shares 4,382,761
Number of grants, vested | shares 1,392,123
Number of grants, unvested | shares 2,990,638
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 15.24
Weighted average exercise price, grants issued | $ / shares 13.70
Weighted average exercise price, grant outstanding ending balance | $ / shares 15.21
Weighted average exercise price, grants vested | $ / shares 15.16
Weighted average exercise price, grants unvested | $ / shares $ 15.23
Weighted Average Remaining Contractual Term, Grants Outstanding 8 years 4 months 24 days
Weighted Average Remaining Contractual Term, Grants Vested 8 years 3 months 18 days
Aggregate Intrinsic Value, grants outstanding | $ $ 0.0
Aggregate Intrinsic Value, grants vested | $ $ 0.0
First Advantage Corporation [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 2,843,342
Number of grants, exercised | shares (85,760)
Number of grants, forfeited | shares (250,856)
Number of units, grant outstanding ending balance | shares 2,506,726
Number of grants, vested | shares 806,379
Number of grants, unvested | shares 1,700,347
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 6.66
Weighted average exercise price, grants issued | $ / shares 6.68
Weighted average exercise price, forefeited | $ / shares 6.69
Weighted average exercise price, grant outstanding ending balance | $ / shares 6.66
Weighted average exercise price, grants vested | $ / shares 6.64
Weighted average exercise price, grants unvested | $ / shares $ 6.67
Weighted Average Remaining Contractual Term, Grants Outstanding 6 years 9 months 18 days
Weighted Average Remaining Contractual Term, Grants Vested 6 years 7 months 6 days
Aggregate Intrinsic Value, grants outstanding | $ $ 18.3
Aggregate Intrinsic Value, grants vested | $ $ 5.9